GenEdit is a next-generation genome editing company

We are developing non-viral delivery technologies for the CRISPR/Cas9 gene editing system that can safely and efficiently correct gene mutations in patients.


New era of genome editing

CRISPR/Cas9 is a powerful genome editing tool that makes therapeutic gene editing possible. It is easier to use, faster, and more accurate than previous gene editing techniques and thus has the potential for a wide range of therapeutic applications.

In particular, CRISPR/Cas9 gene editing has the potential to treat a variety of incurable genetic diseases. However, developing therapeutics based on the CRISPR system has been challenging because of delivery problems.


What we do?

The development of safe and efficient delivery vehicles for CRISPR/Cas9 therapeutics is still an unmet medical need and is necessary for the translation of CRISPR/Cas9 technologies into the clinic.

GenEdit has developed a new delivery vehicle for Cas9/CRISPR based therapeutics, which can encapsulate Cas9 protein, guide RNA, and donor DNA, into a single nanoparticle for more efficient homology directed repair. 

We also work on engineering of core components of CRISPR/Cas9 genome editing system to increase editing efficiency and enable targeted delivery.